Predicting gadolinium enhancement status in MS patients eligible for randomized clinical trials
Authors:
- F. BarkhofFBF. Barkhof
- U. HeldUHU. Held
- J. H. SimonJSJ. H. Simon
- M. DaumerMDM. Daumer
- F. FazekasFFF. Fazekas
- M. FilippiM. Filippi
- J. A. FrankJFJ. A. Frank
- L. KapposLKL. Kappos
- D. LiDLD. Li
- S. MenzlerSMS. Menzler
- D. H. MillerDMD. H. Miller
- J. PetkauJPJ. Petkau
- 8 November 2005
- journal article
- research article
- Published by Wolters Kluwer Health in Neurology
- Vol. 65 (9) , 1447-1454
Abstract
Background: Gadolinium enhancement is often used in randomized clinical trials to evaluate the efficacy of new drugs in multiple sclerosis (MS). Knowledge about predictors of enhancement status is important for the selection of patients for MRI monitored trials. Methods: Data from 17 trials were available in anonymized format through the Sylvia Lawry Centre for MS Research. In an open part containing 1,328 (non primary progressive) patients, two logistic regression analyses were explored, including demographic, clinical, and MRI predictors. The authors examined the area under the curve (AUC) and the increase in positive predictive value (PPV). The final selection of models was validated in a closed part of 848 comparable patients. Results: Age at onset, disease duration, and disease course (CIS/RR/SP) were important predictors from the multivariate models. Further, a multivariate model including T2 burden of disease was more predictive than one with only clinical predictors (AUC 0.719 vs 0.625, p < 0.001). For the model with T2 burden of disease, the PPV was 66.8%, compared to 58.5% for the model without (a priori chance 46.4%). These findings were unequivocally confirmed in the closed part of the database. Conclusion: Gadolinium status can be predicted by a set of baseline variables, certainly when T2 burden of disease is included. These findings may benefit the design and statistical power of future randomized clinical trials.Keywords
This publication has 25 references indexed in Scilit:
- Relapses and Progression of Disability in Multiple SclerosisNew England Journal of Medicine, 2000
- Statistical power of MRI monitored trials in multiple sclerosis: new data and comparison with previous resultsJournal of Neurology, Neurosurgery & Psychiatry, 1999
- Inflammatory central nervous system demyelination: Correlation of magnetic resonance imaging findings with lesion pathologyAnnals of Neurology, 1997
- A preliminary study into the sensitivity of disease activity detection by serial weekly magnetic resonance imaging in multiple sclerosis.Journal of Neurology, Neurosurgery & Psychiatry, 1996
- Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosisAnnals of Neurology, 1996
- Magnetic resonance imaging in monitoring the treatment of multiple sclerosis patients: Statistical power of parallel-groups and crossover designsJournal of the Neurological Sciences, 1994
- Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosisAnnals of Neurology, 1993
- THE PATHOPHYSIOLOGY OF ACUTE OPTIC NEURITISBrain, 1991
- Major differences in the dynamics of primary and secondary progressive multiple sclerosisAnnals of Neurology, 1991
- Indices of discrimination or diagnostic accuracy: Their ROCs and implied models.Psychological Bulletin, 1986